TY  - JOUR
  - O'Connell, J.,Bennett, M. W.,O'Sullivan, G. C.,Collins, J. K.,Shanahan, F.
  - 1999
  - January
  - The Fas counterattack: cancer as a site of immune privilege
  - Validated
  - ()
  - 20
  - 11
  - 46
  - 5246
  - Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fns ligand might enable many cancers to deliver a pre-emptive strike ou counterattack against the immune system. Therapeutic exploitation of this has exciting potential, but now seems more complex and hazardous than teas first evident.Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fns ligand might enable many cancers to deliver a pre-emptive strike ou counterattack against the immune system. Therapeutic exploitation of this has exciting potential, but now seems more complex and hazardous than teas first evident.
  - 0167-56990167-5699
  - ://WOS:000079420600011://WOS:000079420600011
DA  - 1999/01
ER  - 

@article{V235379810,
   = {O'Connell,  J. and Bennett,  M. W. and O'Sullivan,  G. C. and Collins,  J. K. and Shanahan,  F. },
   = {1999},
   = {January},
   = {The Fas counterattack: cancer as a site of immune privilege},
   = {Validated},
   = {()},
   = {20},
   = {11},
  pages = {46--5246},
   = {{Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fns ligand might enable many cancers to deliver a pre-emptive strike ou counterattack against the immune system. Therapeutic exploitation of this has exciting potential, but now seems more complex and hazardous than teas first evident.Resistance to apoptosis through the Fas receptor pathway coupled with expression of the Fns ligand might enable many cancers to deliver a pre-emptive strike ou counterattack against the immune system. Therapeutic exploitation of this has exciting potential, but now seems more complex and hazardous than teas first evident.}},
  issn = {0167-56990167-5699},
   = {://WOS:000079420600011://WOS:000079420600011},
  source = {IRIS}
}